Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest Expenses (2021 - 2025)

Fennec Pharmaceuticals filings provide 7 years of Interest Expenses readings, the most recent being $308000.0 for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 68.12% to $308000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 48.88% decrease, with the full-year FY2025 number at $2.1 million, down 48.88% from a year prior.
  • Interest Expenses hit $308000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $586000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.0 million in Q2 2024 to a low of $4000.0 in Q1 2021.
  • Median Interest Expenses over the past 5 years was $594000.0 (2025), compared with a mean of $566263.2.
  • Biggest five-year swings in Interest Expenses: soared 1350.0% in 2022 and later tumbled 68.12% in 2025.
  • Fennec Pharmaceuticals' Interest Expenses stood at $55000.0 in 2021, then soared by 1561.82% to $914000.0 in 2022, then grew by 0.11% to $915000.0 in 2023, then rose by 5.57% to $966000.0 in 2024, then tumbled by 68.12% to $308000.0 in 2025.
  • The last three reported values for Interest Expenses were $308000.0 (Q4 2025), $586000.0 (Q3 2025), and $594000.0 (Q2 2025) per Business Quant data.